Enter inventor name

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 182(Granted Patents)

Location History:

Welwyn Garden City, Hertfordshire, GB (1983)
Leicestershire, GB (1993 - 1994)
Leics, GB (2000 - 2002)
Loughborough, GB (1994 - 2008)

Company Filing History:

Astra Zeneca U.k. Limited

Astra Pharmaceuticals Limited

patents

5. 1 out of 940

Fujisawa Pharmaceutical Company, Ltd.

patents

6. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1983-2008

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7384950 - Thienopyrimidinediones and their use in the modulation of autoimmune disease (2008-06-10),

2. 7064126 - Compounds (2006-06-20),

3. 6984644 - Treatment of skin disorders using thieno[2,3-D]pyrimidinediones (2006-01-10),

4. 6770646 - Substituted fused pyridazinone compounds; composition and use thereof (2004-08-03),

5. 6469014 - Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy (2002-10-22),

6. 6342601 - Compounds (2002-01-29),

7. 6342502 - Thieno[2,3-d]pyrimidine diones and their use in the treatment of reversible obstructive airways diseases (2002-01-29),

8. 6306863 - Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments (2001-10-23),

9. 6300334 - Thieno[2,3-d]pyrimidine-2,4-diones (2001-10-09),

10. 6211368 - Pyrrolo(3,4-d)pyrimidinone derivatives and their use as medicaments (2001-04-03),

11. 6180635 - Compounds (2001-01-30),

12. 6166206 - Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments (2000-12-26),

13. 6143751 - Pyridine derivatives and pharmaceutical compositions containing them (2000-11-07),

14. 6136974 - Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments (2000-10-24),

15. 6046204 - Pyrrolo[3,4-D] pyrimidinone derivatives and their use as medicaments (2000-04-04),

Title: Martin E Cooper: A Visionary Inventor Shaping the Future

Introduction:

Martin E Cooper, a renowned inventor based in Leicestershire, Great Britain, has made significant contributions to the field of technology through his innovative patents and groundbreaking discoveries. With a portfolio comprising 20 patents, Martin E Cooper's work has revolutionized the landscape of autoimmune disease modulation and pharmaceutical therapies.

Latest Patents:

1. Thienopyrimidinediones and their use in the modulation of autoimmune disease: The invention introduces a compound of formula (1) with novel structural properties and mechanisms for treating autoimmune diseases effectively. The patent encompasses methods of preparation, pharmaceutical compositions, and therapeutic applications in autoimmune disease modulation.

2. Compounds - Thienopyridazinones: Martin E Cooper's patent highlights thienopyridazinones of formula (I) with unique characteristics for therapeutic interventions in autoimmunity. The patent also covers processes for preparation, pharmaceutical compositions, and their application in therapy for autoimmune diseases.

Career Highlights:

Martin E Cooper has established a remarkable career trajectory, having worked with reputable organizations such as AstraZeneca AB and AstraZeneca UK Limited. His relentless pursuit of innovation and scientific advancement has propelled him to the forefront of technological breakthroughs in the pharmaceutical industry.

Collaborations:

Throughout his career, Martin E Cooper has collaborated with esteemed professionals in the field, including David K Donald and David R Cheshire. These collaborations have fostered a culture of knowledge exchange and innovation, leading to the development of groundbreaking solutions in autoimmune disease treatment.

Conclusion:

In conclusion, Martin E Cooper stands as a visionary inventor whose relentless pursuit of innovation has left an indelible mark on the world of technology, inspiring future generations to continue pushing the boundaries of what is possible. His pioneering work in autoimmune disease modulation and pharmaceutical therapies serves as a testament to his dedication to advancing scientific knowledge and improving global health outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com